Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advil campaign targets Tylenol

This article was originally published in The Tan Sheet

Executive Summary

Consumers should empty their medicine cabinets of expired or recalled drugs, Pfizer says, in an ad campaign encouraging them to switch to Advil (ibuprofen) from Johnson & Johnson's Tylenol (acetaminophen). At 1www.MedicineCabinetSafety.com, Pfizer notes Advil was not part of "this year's recalls of certain over-the-counter pain medications" that affected Tylenol and other J&J drugs, and advises consumers to visit FDA's website to learn which products are recalled. Pfizer is giving away 500,000 bottles of Advil to those who register on the site, to help them "replenish their medicine cabinets with a trusted and effective" OTC pain reliever, Pfizer says Oct. 4. The jabs at J&J come as the company makes its first shipments of liquid pediatric OTCs since the April recall (2"The Tan Sheet" Oct. 4, 2010)

You may also be interested in...



J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon

Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel